利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

3 条记录 (耗时 0.011 秒)

    Materials and methods for the detection of nitrated fibrinogen
    1.
    发明授权
    Materials and methods for the detection of nitrated fibrinogen 有权
    用于检测硝化纤维蛋白原的材料和方法

    公开(公告)号：US08852879B2

    公开(公告)日：2014-10-07

    申请号：US12168739

    申请日：2008-07-07

    申请人： Harry Ischiropoulos

    发明人： Harry Ischiropoulos

    IPC分类号： C12Q1/56 ,  G01N33/543 ,  A61K38/36 ,  A61K45/06 ,  A61K38/48 ,  G01N33/86 ,  A61K38/37 ,  G01N33/68 ,  C07K16/36

    CPC分类号： G01N33/6893 ,  A61K38/36 ,  A61K38/363 ,  A61K38/37 ,  A61K38/4833 ,  A61K38/4846 ,  A61K38/4866 ,  A61K45/06 ,  C07K16/36 ,  G01N33/543 ,  G01N33/68 ,  G01N33/86 ,  G01N2333/75 ,  G01N2800/226 ,  G01N2800/324 ,  G01N2800/50 ,  G01N2800/52 ,  A61K2300/00

    摘要： Compositions are disclosed comprising an effective amount of nitrated fibrinogen and a pharmaceutically acceptable carrier for detecting a patient's risk for coronary artery disease. The compositions can be used to determine the presence of nitrated fibrinogen which is linked with coronary artery disease. Also disclosed is a method for determining the presence or risk for coronary artery disease or risk for increased propensity for an adverse thrombotic event in a patient. The method comprises obtaining a sample of blood or fraction thereof from a patient; determining by immunoassay the amount of nitrated fibrinogen in the sample based on binding of the nitrated fibrinogen to an antibody that specifically recognizes SEQ ID NO: 2 and/or SEQ ID NO: 3; and comparing the amount of the antibody-bound nitrated fibrinogen in the sample with the amount of nitrated fibrinogen in a sample from a normal individual, such that a greater amount of nitrated fibrinogen in the patient sample than in the normal individual indicates that the patient has or is at greater risk of coronary artery disease or risk of increased propensity for an adverse thrombotic event. Kits for performing the method which include the composition and aforementioned antibody or antibodies are also provided.

    摘要翻译： 公开了组合物，其包含有效量的硝化纤维蛋白原和用于检测患者冠状动脉疾病风险的药学上可接受的载体。 该组合物可用于确定与冠状动脉疾病相关的硝化纤维蛋白原的存在。 还公开了一种用于确定冠状动脉疾病的存在或风险或患者中不良血栓形成事件倾向增加的风险的方法。 该方法包括从患者获得血液或其部分样品; 基于硝化纤维蛋白原与特异性识别SEQ ID NO：2和/或SEQ ID NO：3的抗体的结合免疫测定样品中硝化纤维蛋白原的量; 并将样品中抗体结合的硝化纤维蛋白原的量与来自正常个体的样品中的硝化纤维蛋白原的量进行比较，使得患者样品中比常规个体更大量的硝化纤维蛋白原表明患者具有 或者患冠状动脉疾病的风险更大或不利血栓事件倾向增加的风险。 还提供了用于进行包括组合物和上述抗体或抗体的方法的试剂盒。